Randomized placebo controlled trial to determine the biological signature of cannabidiol as a treatment for social anxiety disorder

Go Back to All Clinical Trials

Randomized placebo controlled trial to determine the biological signature of cannabidiol as a treatment for social anxiety disorder

Brief description of study

The goals of these two phased studies (“R61” followed by “R33”) are to establish a biological signature of CBD’s putative therapeutic effects in SAD and its link to core SAD symptoms, to provide estimates of clinical effect sizes, and to provide safety and feasibility data to guide a future definitive RCT of CBD for SAD.

Clinical Study Identifier: s22-00568

Principal Investigator: Naomi M. Simon.

Other Investigators: Matteo Malgaroli, Michele Santacatterina, Kristin L Szuhany, Benjamin Feldman, Esther Blessing.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies